EQ 500 - Zyvex Pharmaceuticals
EQ 500 (Boldenone Undecylenate) - Zyvex Pharmaceuticals Overview
EQ 500 by Zyvex Pharmaceuticals contains Boldenone Undecylenate at 500 mg per milliliter in a 10 ml multi-dose vial - 5,000 mg total per vial. EQ 500 is the high-concentration formulation of Equipoise, containing the same active compound as EQ 300 but at a higher concentration per milliliter. At matched weekly doses, EQ 500 and EQ 300 produce identical pharmacological effects - the only practical difference is injection volume. EQ 500 is designed for experienced users running 500 mg per week or more who want to keep injection volumes low. At 500 mg/week, EQ 300 requires 1.67 ml per week while EQ 500 requires exactly 1.0 ml.
Boldenone Undecylenate is a testosterone derivative with an additional double bond at the C1-C2 carbon position. This structural modification reduces aromatization to approximately 50% of testosterone's rate and eliminates progestogenic activity entirely - unlike Nandrolone-based compounds (Deca, NPP), EQ does not require Cabergoline. The undecylenate ester is an 11-carbon chain, giving EQ 500 a half-life of approximately 14 days. The compound is not hepatotoxic, making it suitable for the long 12-16 week cycles that its slow build-up requires. EQ 500 is known for lean, dry mass gains, pronounced appetite stimulation, and significant red blood cell production that improves endurance and vascularity.
About the Compound: Boldenone Undecylenate 500 mg/ml
Boldenone is a naturally occurring anabolic steroid - the only naturally occurring anabolic steroid besides testosterone, found in trace amounts in cattle. The injectable form used in bodybuilding attaches the undecylenate ester to the boldenone base: an 11-carbon chain that is one of the longest esters available, responsible for the approximately 14-day half-life and the slow, steady blood level curve that characterizes all Boldenone preparations. Full saturation of blood levels after starting EQ 500 at a consistent weekly dose takes approximately 4-5 weeks - which is why cycles under 12 weeks are suboptimal and experienced users prefer 14-16 week runs.
The C1-C2 double bond modification of boldenone produces two pharmacologically important differences from testosterone. First, aromatization to estrogen is reduced to approximately 50% of testosterone's rate - this translates to significantly less water retention and a lower estrogen-driven blood pressure elevation at equivalent weekly doses. Second, progestogenic activity is eliminated. Boldenone does not bind progesterone receptors. This is the critical distinction from Nandrolone: Deca and NPP require Cabergoline as prolactin management, EQ does not. At 500 mg/ml, EQ 500 delivers 5,000 mg per 10 ml vial - enough for a full 10-week cycle at 500 mg/week.
EQ 500 vs EQ 300: Which Concentration to Choose
EQ 500 and EQ 300 contain the same active substance - Boldenone Undecylenate - and produce completely identical effects at matched weekly doses. The only difference is concentration per milliliter. EQ 500 at 500 mg/ml is a higher-concentration oil: it requires less volume per injection to hit a given weekly dose, but higher concentration oils are more prone to post-injection pain (PIP), particularly at smaller injection sites like the deltoid. EQ 300 at 300 mg/ml is more comfortable to inject. EQ 500 becomes the practical choice at 500 mg/week and above, where the volume reduction is genuinely useful. Below 500 mg/week, EQ 300 is generally the better choice for comfort.
| Weekly Dose | Volume with EQ 300 (300 mg/ml) | Volume with EQ 500 (500 mg/ml) | Best Format |
|---|---|---|---|
| 300 mg/week | 1 ml total (0.5 ml x2) | 0.6 ml total (0.3 ml x2) | EQ 300 (more comfortable) |
| 400 mg/week | 1.33 ml total (0.67 ml x2) | 0.8 ml total (0.4 ml x2) | Either |
| 500 mg/week | 1.67 ml total (0.83 ml x2) | 1 ml total (0.5 ml x2) | EQ 500 (volume advantage starts here) |
| 600 mg/week | 2 ml total (1 ml x2) | 1.2 ml total (0.6 ml x2) | EQ 500 (lower injection volume clear) |
EQ 500 is not recommended for a first EQ cycle. Users who have not run Boldenone before should start with EQ 300 at 300-400 mg/week to establish individual response and tolerability before committing to higher doses or higher concentration formulations.
What EQ 500 Does
Boldenone Undecylenate produces a distinct effect profile that separates it from both testosterone and Nandrolone. The gains are lean, dry, and relatively slow to accumulate, but they are of higher quality and better retained post-cycle than the wetter gains typical of testosterone cycles at equivalent doses.
- Lean, quality mass gains - EQ 500 stimulates protein synthesis and nitrogen retention with significantly less water retention than testosterone due to its lower aromatization rate. The mass gained is drier and more visible during the cycle. Total mass accumulation is slower than a comparable testosterone cycle, but a larger proportion is retained post-cycle because it is not water-dependent.
- Appetite stimulation - One of Boldenone's most distinctive and well-documented effects is a pronounced increase in appetite. Users consistently report significantly elevated hunger within 2-4 weeks of starting EQ - more so than testosterone at equivalent doses. For users in a caloric surplus phase where high food intake is the goal, this practical advantage makes hitting caloric targets considerably easier.
- Endurance and red blood cell production - EQ 500 is a potent stimulator of erythropoiesis. More than testosterone at equivalent doses, Boldenone increases hematocrit and red blood cell count, improving oxygen delivery to working muscle, enhancing endurance capacity, reducing fatigue during high-volume training, and accelerating removal of metabolic waste products. This effect also makes EQ a popular choice for athletes who do cardiovascular or high-volume training alongside their resistance work.
- Vascularity - The combination of lean, low-water mass accumulation and increased red blood cell volume produces pronounced vascular definition on EQ cycles. Visible vascularity in the forearms, arms, and shoulders increases as the cycle progresses, making EQ 500 a commonly chosen compound for lean bulk phases where aesthetics during the cycle matter alongside the mass-building objective.
EQ does NOT require prolactin management: Boldenone Undecylenate is not a progestin and does not bind progesterone receptors. This distinguishes it fundamentally from Nandrolone (Deca 300, Deca 500, NPP) where prolactin elevation and the requirement for Cabergoline is a real concern. EQ cycles do not require Cabergoline. What EQ does require is an aromatase inhibitor on-cycle (at a lower dose than testosterone cycles) and a testosterone base to maintain physiological function while endogenous production is suppressed.
Dosing and Cycle Protocols
| Experience Level | Weekly Dose | Injection Schedule | Cycle Length | Notes |
|---|---|---|---|---|
| Intermediate (first EQ cycle) | 300-400 mg/week | 2x per week (e.g., Mon + Thu) | 12-14 weeks | At this dose, EQ 300 is more comfortable than EQ 500. Stack with Testosterone Enanthate or Cypionate 300-400 mg/week. Anastrozole 0.25 mg every other day. No Cabergoline needed. |
| Advanced | 500 mg/week | 2x per week | 14-16 weeks | EQ 500 is practical at this dose (1 ml/week total). Stack with Testosterone Enanthate or Cypionate 400-500 mg/week. Bloodwork at weeks 6-8 to check hematocrit. |
| High-dose (experienced only) | 600 mg/week | 2x per week | 14-16 weeks | EQ 500 significantly reduces injection volume at this dose (1.2 ml/week vs 2 ml/week with EQ 300). Donate blood if hematocrit exceeds 52% on mid-cycle bloodwork. |
EQ 500 must always be run with a testosterone base at minimum 200 mg/week. Boldenone suppresses natural testosterone production from the first injection. Running EQ without a testosterone base produces progressive low-T symptoms (fatigue, low libido, mood decline) that worsen as endogenous production approaches zero. The testosterone base maintains physiological function while Boldenone provides the primary anabolic drive for the cycle.
Side Effects and Management
| Side Effect | Background | Management |
|---|---|---|
| Elevated hematocrit (primary concern) | EQ 500's most clinically significant side effect. Boldenone is a potent stimulator of erythropoiesis - more so than testosterone at equivalent doses. Hematocrit can rise substantially over a 12-16 week cycle at 500-600 mg/week, increasing blood viscosity and cardiovascular risk including hypertension, clotting, and stroke. This is the side effect requiring the most active monitoring on EQ cycles. | Bloodwork every 6-8 weeks on-cycle to check hematocrit. If hematocrit exceeds 52%, donate blood (therapeutic phlebotomy, 250-500 ml) - this reduces red blood cell mass effectively within days. Stay well-hydrated throughout the cycle. Do not begin a new cycle until hematocrit has returned to normal on post-cycle bloodwork. |
| Estrogen-related effects (mild) | Boldenone aromatizes to estradiol at approximately 50% the rate of testosterone. At typical EQ doses, estrogen elevation is moderate. Water retention and gynecomastia risk are lower than with equivalent testosterone doses. The issue compounds when EQ 500 is run alongside a testosterone base: combined aromatization from both compounds adds up and the AI dose must account for both. | AI at a lower dose than a testosterone-only cycle: Anastrozole 0.25 mg every other day or Exemestane 12.5 mg every other day is typically sufficient. Adjust based on bloodwork estradiol. Do not over-suppress estrogen - some is required for joint health, libido, and cardiovascular function. |
| HPTA suppression | EQ suppresses LH and FSH from the first injection. The 14-day half-life means active suppression continues for several weeks after the last injection - longer than with short-ester compounds. Running EQ without a testosterone base causes progressive low-T symptoms as endogenous production reaches zero. | Testosterone base (minimum 200 mg/week) throughout the entire cycle. Begin PCT 21 days after the last EQ 500 injection to allow adequate clearance of the undecylenate ester. |
| Post-injection pain (PIP) | EQ 500 at 500 mg/ml is more prone to post-injection pain than lower concentration Boldenone formulations. The higher concentration of active compound in the carrier oil creates more local tissue irritation. This is more pronounced at smaller injection sites (deltoid) than at larger sites (ventrogluteal). | Warm the vial in warm water before drawing to reduce oil viscosity. Inject slowly (30-60 seconds per ml). Use the ventrogluteal site as the primary injection site. Rotate sites consistently. Consider mixing EQ 500 with the testosterone base in the same syringe to dilute the concentration at the injection site. |
| Androgenic effects (acne, hair loss) | EQ has a moderate androgenic rating (~50 vs testosterone's 100). Androgenic side effects are generally less pronounced than with testosterone at matched doses, but acne and oily skin occur at higher doses in sensitive individuals. Hair loss risk in genetically predisposed users is present but less severe than with testosterone or Trenbolone. | Topical treatments for acne. Rotate and clean injection sites. Note: Finasteride does not effectively block EQ's androgenic effects - Boldenone does not convert via 5-alpha-reductase to the same degree as testosterone, so 5-AR inhibitors provide minimal protection against EQ-driven androgenic sides. |
Post-Cycle Therapy
The 14-day half-life of Boldenone Undecylenate requires a longer wait before starting PCT than shorter-ester compounds. After the last injection of EQ 500, the compound remains active and suppressive for approximately 3-4 weeks. Starting PCT while active Boldenone is still circulating is counterproductive - the HPTA suppression continues while the SERM attempts to restart LH and FSH production. Wait 21 days after the last EQ 500 injection before starting PCT. When EQ 500 is run alongside Testosterone Enanthate or Cypionate, the 21-day wait covers both compounds. Always confirm hematocrit has normalized on post-cycle bloodwork before planning the next cycle.
| PCT Protocol | Drugs and Doses | Duration |
|---|---|---|
| Standard (EQ + Test cycle, 12-14 weeks) | Clomid 50 mg/day, or Nolvadex 20 mg/day. Either alone is adequate for a standard cycle. Both together (Clomid 50 mg + Nolvadex 20 mg daily) for more aggressive recovery. | 4 weeks. Start 21 days after the last EQ 500 injection. |
| Long cycle (14-16 weeks at high dose) | Clomid 100 mg/day for weeks 1-2, then 50 mg/day for weeks 3-4. Nolvadex 20 mg/day throughout all 4-6 weeks of PCT. | 4-6 weeks. Confirm recovery with bloodwork (LH, FSH, total testosterone, free testosterone) 4-6 weeks post-PCT. Confirm hematocrit normalized before next cycle. |
Frequently Asked Questions
What is EQ 500 and what does it contain?
EQ 500 by Zyvex Pharmaceuticals contains Boldenone Undecylenate at 500 mg per milliliter in a 10 ml multi-dose vial, for 5,000 mg total. "EQ" is shorthand derived from Equipoise, the original Squibb veterinary brand name for Boldenone Undecylenate. EQ 500 is a high-concentration formulation of the same compound found in EQ 300 - at matched weekly doses the pharmacological effects are identical. The 500 mg/ml concentration is designed for users running 500 mg per week or more who want to reduce injection volume per pin. Boldenone Undecylenate is a modified testosterone with an additional double bond at the C1-C2 position, which reduces its aromatization rate to approximately 50% of testosterone and eliminates progestogenic activity entirely. The undecylenate ester (11 carbons) produces a half-life of approximately 14 days. EQ 500 is not hepatotoxic, making it suitable for 12-16 week cycles.
What is the difference between EQ 500 and EQ 300?
EQ 500 and EQ 300 contain the same active compound - Boldenone Undecylenate - at different concentrations: 500 mg/ml versus 300 mg/ml. At matched weekly doses, the pharmacological effects, gains, and side effect profile are completely identical. The practical difference is injection volume and injection comfort. At 300 mg/week, EQ 300 requires 1.0 ml total per week while EQ 500 requires only 0.6 ml. At 500 mg/week, EQ 300 requires 1.67 ml per week while EQ 500 requires exactly 1.0 ml. Higher concentration oils like EQ 500 are more prone to post-injection pain (PIP) - the oil is more irritating at the injection site than lower concentration formulations. For users running 300-400 mg/week, EQ 300 is the better choice because the injection volumes are manageable and PIP is lower. EQ 500 becomes the practical choice at 500 mg/week and above, where the reduced injection volume is worth the slightly higher PIP risk.
Is EQ 500 suitable for beginners or a first EQ cycle?
No - EQ 500 is not recommended for a first EQ cycle or for inexperienced users. There are two reasons. First, users who have never run Boldenone should start at 300-400 mg per week to assess individual response, tolerability, and how their body handles the compound's distinctive effects (strong appetite stimulation, hematocrit elevation, slow build-up). Starting at the higher doses that make EQ 500 practical - 500+ mg/week - is not appropriate before that baseline is established. Second, EQ 500 at 500 mg/ml causes more post-injection pain than EQ 300 at 300 mg/ml. Users new to injectables or to Boldenone in particular should use EQ 300 for a more comfortable introduction. EQ 500 is appropriate for experienced users who know their response to Boldenone and are running doses of 500 mg/week or higher where the injection volume reduction is genuinely useful.
How do I manage post-injection pain (PIP) with EQ 500?
EQ 500 at 500 mg/ml is more prone to post-injection pain than lower concentration Boldenone formulations. The higher concentration of active compound in the carrier oil creates more local tissue irritation at the injection site. To minimize PIP with EQ 500: warm the vial in warm (not hot) water for 2-3 minutes before drawing to reduce oil viscosity; inject slowly - 30-60 seconds per milliliter is the correct pace, never rapid injection; use the ventrogluteal site (side of the hip) as the primary injection site - it has the most muscle mass and the lowest nerve/vessel risk, tolerating larger volumes better than the deltoid; rotate injection sites consistently and never inject the same site on consecutive pins; if PIP is severe, mixing EQ 500 with a lower concentration oil (for example, drawing your testosterone enanthate in the same syringe) reduces the effective boldenone concentration at the injection site. Some degree of PIP with EQ 500 is normal and does not indicate a product problem.
Why do EQ 500 cycles need to be at least 12 weeks?
The minimum 12-week cycle length is a direct consequence of the undecylenate ester's 14-day half-life. Because the compound releases slowly into circulation, it takes approximately 4-5 weeks from the first injection to reach stable, saturated blood levels where peak anabolic effects are being produced consistently. A cycle of 6-8 weeks would spend nearly half its duration in the build-up phase and would need to end just as the compound reaches peak effectiveness - wasting both the compound and the cycle. The benefits of EQ continue accumulating well into weeks 10-16 as blood levels remain stable, which is why 14-16 week cycles are preferred by experienced users. This long build-up is the fundamental pharmacokinetic trade-off of the undecylenate ester: slower onset requires planning for a longer runway, but the payoff is stable blood levels with minimal fluctuation throughout the cycle.
Does EQ 500 require Cabergoline or prolactin management?
No - EQ 500 does not require Cabergoline or any prolactin management. Boldenone Undecylenate is not a progestin and does not bind progesterone receptors. This is a fundamental pharmacological difference from Nandrolone-based compounds (Deca, NPP), where progesterone receptor activity contributes to prolactin elevation and associated side effects including lactation and sexual dysfunction. Users who include Cabergoline as a precaution on EQ cycles do not need to do so - it is unnecessary. What EQ 500 does require is an aromatase inhibitor on-cycle (at a lower dose than a testosterone-only cycle, since EQ's aromatization rate is approximately half that of testosterone) and a testosterone base to maintain physiological function while natural production is suppressed.
How should I monitor hematocrit on an EQ 500 cycle?
Hematocrit monitoring is mandatory on all EQ cycles and is more critical on longer or higher-dose cycles like those typically run with EQ 500. Boldenone's potent red blood cell stimulation can substantially raise blood viscosity over a 12-16 week cycle - this is EQ's primary cardiovascular concern, not water retention. Get baseline bloodwork before starting the cycle, including a complete blood count (CBC) to establish your starting hematocrit. Recheck hematocrit at the midpoint of the cycle (weeks 6-8) and again at the end. Normal male hematocrit range is approximately 38.3% to 48.6% - if your hematocrit rises above 52-54%, take action: reduce EQ dose, shorten the cycle, or donate blood (therapeutic phlebotomy). Do not start a new cycle until hematocrit has returned to normal on post-cycle bloodwork. Ignoring elevated hematocrit increases blood viscosity and cardiovascular risk, including thrombosis risk.
When do I start PCT after EQ 500?
Wait 21 days after the last injection of EQ 500 before starting PCT. The 14-day half-life of the undecylenate ester requires a longer clearance window than testosterone esters - starting PCT too early, while active Boldenone is still suppressing LH and FSH, is counterproductive and wastes the PCT medications. In most EQ cycles that include a testosterone base (Enanthate or Cypionate), the 21-day wait covers both compounds. PCT protocol after a standard EQ + Test cycle (12-14 weeks): Clomid 50 mg/day for 4 weeks, or Nolvadex 20 mg/day for 4 weeks. After an extended cycle (14-16 weeks): Clomid 100 mg/day for weeks 1-2 then 50 mg/day weeks 3-4, plus Nolvadex 20 mg/day throughout the PCT. Also confirm hematocrit has returned to normal range on post-cycle bloodwork before planning the next cycle.
Related Products
- Promotes lean muscle growth and strength.
- Enhances endurance and recovery.
- Supports fat loss with minimal water retention.
- Delivers sustained anabolic effects.
- Promotes steady lean muscle growth and strength.
- Enhances endurance via increased red blood cell production.
- Supports fat loss for a defined physique.
- Delivers high-quality gains with minimal water retention.
- Promotes steady lean muscle growth and strength.
- Enhances endurance via increased red blood cell production.
- Supports fat loss for a defined physique.
- Delivers high-quality gains with minimal water retention.
